What You Should Know:
- Personalis, Inc. (NASDAQ: PSNL) today announced agreements with long-time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy.
- The company has received a $50M investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
eClinical Solutions & Snowflake Integrate Clinical Data Management
What You Should Know:
- eClinical Solutions LLC, a global leader in digital clinical software and services, has announced a strategic collaboration with Snowflake, the AI Data Cloud company.
- This partnership establishes a bidirectional integration designed to address the growing challenges in managing clinical data while enabling life sciences organizations to unlock greater value through a modern clinical data architecture.
eClinical Solutions Partners with Snowflake to Enhance
Read More
BrightInsight, Sanofi to Build Drug Companion Apps for its Major Specialty Therapies
What You Should Know:
- BrightInsight, Inc., a provider of regulated digital health solutions, has announced an expanded multi-year partnership with Sanofi, a global biopharmaceutical company. This expanded partnership builds on a successful collaboration that began in 2022 when Sanofi selected the BrightInsight Platform to accelerate the development of a SaMD for one of its specialty care medicines.
- The goal of the collaboration aims to accelerate Sanofi's drug development timeline and
Read More
The Role of AI in Streamlining Cannabis Dosage Recommendations
The use of medical cannabis is gaining traction for managing a wide range of conditions, from pain to stress. However, determining the right dosage remains a significant challenge.
Factors such as individual metabolism, tolerance levels, and body composition can influence how product potency affects individuals. While you can use these factors to make an educated guess on dosage, pinpointing the ideal potency level often takes experimentation.
However, artificial intelligence
Read More
Promise Bio Secures $8.3M for Auto-Immune Precision Medicine Platform
What You Should Know:
- Promise Bio, a startup transforming immune-mediated disease treatment with advanced precision medicine solutions, today announced its emergence from stealth with an $8.3 million seed investment.
- This funding will accelerate the development of Promise Bio's computational platform, which uses epiproteomics and artificial intelligence to predict patient treatment responses and support drug research and development.
Revolutionizing Immune-Mediated Disease
Read More
Pleno Closes $25M Series B & Appoints Dr. Vik Vaz as CEO
What You Should Know:
- Pleno, an innovative multi-omics diagnostics company, announced it has raised $25M in Series B funding and appointed Dr. Vik Vaz as its new Chief Executive Officer (CEO). Key investors Deerfield Management, Foresite Capital and Medical Excellence Capital remain committed to supporting the next phase of the company’s growth strategy.
- Dr. Vaz, a seasoned leader with extensive experience in the life sciences and medical technology sectors, will guide
Read More
Capstan Medical Raises $110M to Advance Minimally Invasive Heart Valve Treatment
What You Should Know:
- Capstan Medical, a medical technology company developing innovative solutions for heart valve disease secures $110M in a Series C funding round led by Eclipse with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.
- Capstan Medical is developing a suite of next-generation heart valve implants and a first-of-its-kind catheter-based robotic delivery platform.
Addressing the Global Burden
Read More
Nucs AI Secures $3.5M to Advance AI-Powered Prostate Cancer Diagnostics
What You Should Know:
- Nucs AI, a company that uses AI in precision medicine for the diagnosis and treatment of prostate cancer, today announces that it has closed a $3.5 million seed round of funding.
- The company will use the funding to further build out its platform and to support FDA clearance for its technology in the United States.
Nucs AI: Transforming Prostate Cancer Diagnosis and Treatment with Precision Medicine
Founded in 2023, Nucs AI is pioneering advancements in
Read More
H1 and CTI Partner for Clinical Trial Optimization
What You Should Know:
- H1, on a mission to connect the world to the right doctors, today announced a strategic partnership with CTI Clinical Trial & Consulting Services (CTI), a leading global full-spectrum research service provider.
- Through this partnership, CTI will leverage H1’s Trial Landscape platform to drive data-informed clinical trial planning and execution to enhance strategic feasibility, real-world evidence, and clinical trial execution on a global scale. This
Read More
Carta Healthcare Acquires Realyze Intelligence to Enhance AI-Powered Clinical Trial Matching
What You Should Know:
- Carta Healthcare®, which ignites healthcare improvement by unlocking the power of clinical data, expanded the strength and capabilities of its AI-powered platform with the acquisition of Realyze Intelligence.
- The Realyze Intelligence solution leverages AI to match patients to clinical trials to accelerate research and reduce costs while providing patients with the latest advances in care.
Carta Healthcare and Realyze Intelligence:
Read More
